Abstract
Angiogenesis is a developmental process that also plays the central role in adults during the female menstruation cycle, wound healing and neoplastic growth and metastasis. Ideally, blocking neovessel growth starves the developing tumor and induces tumor regression. Restricting the vascular ingrowth into the tumor might have adverse effect on drugs targeting the tumor. Nevertheless, anti-VEGF treatment of the neoplastic diseases when combined with chemotherapy significantly increases median survival in treated patients. This suggests alternative mechanisms of anti-angiogenesis therapy. A number of molecules that are in current clinical trials have been identified using angiogenesis models. However, current angiogenesis models have advantages and inconvenience and conclusion drawn upon their use should be interpreted with caution. Thus, it is necessary to optimize existing models and to develop new ones that take into account the complexity of the angiogenic process as it happens in many angiogenesis-related diseases and in particular in cancer.
Keywords: Angiogenesis, animal models, in vitro models, tumor vasculature, vessel normalization
Current Pharmaceutical Biotechnology
Title: Recent Developments in Tumor Angiogenesis
Volume: 8 Issue: 1
Author(s): W. W. Kilarski and A. Bikfalvi
Affiliation:
Keywords: Angiogenesis, animal models, in vitro models, tumor vasculature, vessel normalization
Abstract: Angiogenesis is a developmental process that also plays the central role in adults during the female menstruation cycle, wound healing and neoplastic growth and metastasis. Ideally, blocking neovessel growth starves the developing tumor and induces tumor regression. Restricting the vascular ingrowth into the tumor might have adverse effect on drugs targeting the tumor. Nevertheless, anti-VEGF treatment of the neoplastic diseases when combined with chemotherapy significantly increases median survival in treated patients. This suggests alternative mechanisms of anti-angiogenesis therapy. A number of molecules that are in current clinical trials have been identified using angiogenesis models. However, current angiogenesis models have advantages and inconvenience and conclusion drawn upon their use should be interpreted with caution. Thus, it is necessary to optimize existing models and to develop new ones that take into account the complexity of the angiogenic process as it happens in many angiogenesis-related diseases and in particular in cancer.
Export Options
About this article
Cite this article as:
Kilarski W. W. and Bikfalvi A., Recent Developments in Tumor Angiogenesis, Current Pharmaceutical Biotechnology 2007; 8 (1) . https://dx.doi.org/10.2174/138920107779941444
DOI https://dx.doi.org/10.2174/138920107779941444 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
25th Anniversary Special Issue.
Current Pharmaceutical Biotechnology (CPB) is celebrating its 25th anniversary with a special issue highlighting the journal’s growth and its pivotal contributions to innovation and knowledge in academia. Since its inaugural issue in 2000, CPB has fostered a multidisciplinary platform for emerging scholars to publish high-quality research in pharmaceutical biotechnology. Over ...read more
Applications and Challenges of Nano-Biotechnology
This thematic issue aims to introduce readers to the fascinating intersection of nanotechnology and biology. It will bring together fundamental principles, materials, tools, and recent breakthroughs to help learners, researchers, and innovators understand how nanoscale science is revolutionizing biological and medical applications. Contributing authors will submit papers related to foundational ...read more
Latest Advancements in Biotherapeutics.
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
Machine Learning and Artificial Intelligence for Medical Data Analysis and Human Information Analysis in Healthcare
The intersection of machine learning (ML) and artificial intelligence (AI) with the pharmaceutical industry is revolutionizing traditional paradigms in drug discovery and development. These technologies have introduced innovative approaches to analyzing complex datasets and predicting chemical properties, leading to more efficient identification and optimization of drug candidates. By employing sophisticated ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity
Current Genomics GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Evaluating the Susceptibility of Mitochondrial DNA Germline Mutations in Chinese Cancer Patients
Current Molecular Medicine Identification of Novel Indazole-based Inhibitors of Fibroblast Growth Factor Receptor 1 (FGFR1)
Current Enzyme Inhibition Mitochondria: A Promising Target for Anticancer Alkaloids
Current Topics in Medicinal Chemistry The Opposite Effect of L-kynurenine and Ahr Inhibitor Ch223191 on Apoptotic Protein Expression in Pancreatic Carcinoma Cells (Panc-1)
Anti-Cancer Agents in Medicinal Chemistry Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?
Current Drug Targets Current Targets for Anticancer Drug Discovery
Current Drug Targets Allelic Variations in 5, 10-Methylenetetrahydrofolate Reductase Gene and Susceptibility to Cervical Cancer in Indian Women
Drug Metabolism Letters Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?
Current Cancer Drug Targets Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Current Pharmaceutical Biotechnology The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry Polyphenols in Food: Cancer Prevention and Apoptosis Induction
Current Medicinal Chemistry The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features
Current Drug Targets Saccharomyces Cerevisiae as a Genetic Model in Anticancer Therapy
Current Pharmacogenomics Defining the Role of Integrin αvβ6 in Cancer
Current Drug Targets Formulating SLN and NLC as Innovative Drug Delivery Systems for Non-Invasive Routes of Drug Administration
Current Medicinal Chemistry Improvement of Tumor Localization of Photosensitizers for Photodynamic Therapy and Its Application for Tumor Diagnosis
Current Topics in Medicinal Chemistry Oncogene-Directed Therapies as Modulators of Cancer Coagulopathy, Angiogenesis and Tumor-Vascular Interface
Current Signal Transduction Therapy